Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  All
Drug:  Gleevec
Find trials that include:  Any drugs shown
Results 1-10 of 10 for your search:
Start Over
Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 2 to 21
Trial IDs: AALL1631, NCI-2016-01588, NCT03007147
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0697, NCI-2013-00551, NCT01751425
Binimetinib and Imatinib Mesylate in Treating Patients with Untreated Advanced Gastrointestinal Stromal Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-162, NCI-2013-02281, NCT01991379
Pembrolizumab and Imatinib Mesylate in Treating Patients with Locally Advanced or Metastatic Melanoma with c-KIT Mutation or Amplification
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: OSU-15280, NCI-2016-00864, 2016C0097, NCT02812693
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride with Asparaginase in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9459, NCI-2015-01402, CC9459, NCT02538926
Dasatinib or Nilotinib Followed by Imatinib Mesylate in Treating Patients with Newly Diagnosed, Previously Untreated, Chronic Phase Chronic Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 17 and over
Trial IDs: Winship3143-16, NCI-2016-00162, IRB00087045, NCT02709083
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 9770, NCI-2016-02050, NCT03023046
Ipilimumab and Imatinib Mesylate in Advanced Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 15 and over
Trial IDs: 2012-0784, NCI-2013-00030, NCT01738139
Start Over